Description
Balchem Corporation’s VitaCholine Breakthrough: Could Women’s Cognitive Health Unlock A New Market?
Balchem Corporation reported strong financial and operational results for the first quarter of 2026, continuing a prolonged trend of growth with the 27th consecutive quarter of year-over-year adjusted EBITDA expansion. Consolidated sales reached a record $271 million, up 8.1% from the prior year, driven by positive contributions across all three segments: Human Nutrition & Health, Animal Nutrition & Health, and Specialty Products. Adjusted EBITDA rose 12.1% to $74 million, and adjusted diluted earnings per share increased 9% to $1.33. The company also generated robust cash flows, with $40 million from operations and free cash flow of $34 million, accompanied by a well-managed balance sheet with net debt of $96 million and a leverage ratio of 0.3 times. The Human Nutrition & Health segment demonstrated solid growth, with sales up 8.
Our Report Structure:
⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
⦁ Disclosures
Want unlimited access to our reports? Purchase our $399 annual subscription!
